Baker Bros. Advisors LP Immunovant, Inc. Transaction History
Baker Bros. Advisors LP
- $9.86 Billion
- Q2 2025
A detailed history of Baker Bros. Advisors LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 5,457,881 shares of IMVT stock, worth $150 Million. This represents 1.52% of its overall portfolio holdings.
Number of Shares
5,457,881
Previous 5,457,881
-0.0%
Holding current value
$150 Million
Previous $150 Million
-0.0%
% of portfolio
1.52%
Previous 1.79%
Shares
5 transactions
Others Institutions Holding IMVT
# of Institutions
192Shares Held
78.7MCall Options Held
401KPut Options Held
354K-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$193 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.88MShares$189 Million0.07% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$143 Million2.5% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...